NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the…
Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum
Aurentis Capital Group Announces Technology-Driven Trading Platform for Global Markets
TMX Group Limited Completes Acquisition of RAFI Indices from Research Affiliates
Focus Graphite Chairman Converts Final C$835,000 Loan to Equity at a Premium to Market
Hong Kong emerges as top professional services platform for Mainland enterprises going global